| Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015–20): a comparative analysis UJ Muehlematter, P Daniore, KN Vokinger The Lancet Digital Health 3 (3), e195-e203, 2021 | 485 | 2021 |
| Mitigating bias in machine learning for medicine KN Vokinger, S Feuerriegel, AS Kesselheim Communications medicine 1 (1), 25, 2021 | 204 | 2021 |
| Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis KN Vokinger, TJ Hwang, T Grischott, S Reichert, A Tibau, T Rosemann, ... The Lancet Oncology 21 (5), 664-670, 2020 | 186 | 2020 |
| Lifecycle regulation of artificial intelligence–and machine learning–based software devices in medicine TJ Hwang, AS Kesselheim, KN Vokinger Jama 322 (23), 2285-2286, 2019 | 145 | 2019 |
| Vertebral body insufficiency fractures: detection of vertebrae at risk on standard CT images using texture analysis and machine learning UJ Muehlematter, M Mannil, AS Becker, KN Vokinger, T Finkenstaedt, ... European radiology 29, 2207-2217, 2019 | 121 | 2019 |
| Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study TJ Hwang, JS Ross, KN Vokinger, AS Kesselheim bmj 371, 2020 | 95 | 2020 |
| Digital health and the COVID-19 epidemic: an assessment framework for apps from an epidemiological and legal perspective KN Vokinger, V Nittas, CM Witt, SI Fabrikant, V Von Wyl Swiss medical weekly 150, w20282, 2020 | 93 | 2020 |
| Continual learning in medical devices: FDA's action plan and beyond KN Vokinger, S Feuerriegel, AS Kesselheim The Lancet Digital Health 3 (6), e337-e338, 2021 | 69 | 2021 |
| Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe KN Vokinger, TJ Hwang, P Daniore, CWC Lee, A Tibau, T Grischott, ... JAMA oncology 7 (9), e212026-e212026, 2021 | 64 | 2021 |
| Strategies that delay market entry of generic drugs KN Vokinger, AS Kesselheim, J Avorn, A Sarpatwari JAMA internal medicine 177 (11), 1665-1669, 2017 | 63 | 2017 |
| Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy J Mwinyi, K Vokinger, A Jetter, U Breitenstein, C Hiller, GA Kullak-Ublick, ... Cancer chemotherapy and pharmacology 73, 1181-1188, 2014 | 49 | 2014 |
| Lost in anonymization—a data anonymization reference classification merging legal and technical considerations KN Vokinger, DJ Stekhoven, M Krauthammer The Journal of Law, Medicine & Ethics 48 (1), 228-231, 2020 | 48 | 2020 |
| Regulating AI in medicine in the United States and Europe KN Vokinger, U Gasser Nature machine intelligence 3 (9), 738-739, 2021 | 43 | 2021 |
| Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU KN Vokinger, AS Kesselheim BMJ open 9 (10), e028634, 2019 | 42 | 2019 |
| Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe from 2007 to 2021 KN Vokinger, AS Kesselheim, CEG Glaus, TJ Hwang JAMA Health Forum 3 (8), e222685-e222685, 2022 | 38 | 2022 |
| FDA-cleared artificial intelligence and machine learning-based medical devices and their 510 (k) predicate networks UJ Muehlematter, C Bluethgen, KN Vokinger The Lancet Digital Health 5 (9), e618-e626, 2023 | 35 | 2023 |
| Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis KN Vokinger, TJ Hwang, DL Carl, Y Laube, WD Ludwig, H Naci, ... The Lancet Oncology 23 (4), 514-520, 2022 | 32 | 2022 |
| Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland DL Carl, Y Laube, M Serra-Burriel, H Naci, WD Ludwig, KN Vokinger JAMA network open 5 (12), e2244670-e2244670, 2022 | 27 | 2022 |
| Clinical benefit and expedited approval of cancer drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia TJ Hwang, AS Kesselheim, A Tibau, CWC Lee, KN Vokinger JCO Oncology Practice 18 (9), e1522-e1532, 2022 | 23 | 2022 |
| Accessibility of cancer drugs in Switzerland: time from approval to pricing decision between 2009 and 2018 KN Vokinger, UJ Muehlematter Health Policy 124 (3), 261-267, 2020 | 23 | 2020 |
